✦ LIBER ✦

Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization

✍ Scribed by Prakash Vishnu; Vivek Roy; Athena Paulsen; Abba C. Zubair

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Cost-Benefit Analysis of Pl

✍ P. Vishnu; V. Roy; A. Paulsen; A.C. Zubair 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Pegfilgrastim- versus filgrastim-based a

✍ Luciano J. Costa; Cindy Kramer; Kathy R. Hogan; Coleen D. Butcher; Amanda L. Lit 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 243 KB

Cost-Effectiveness Analysis of a Risk-Ad

✍ Micallef, Ivana N.M.; Sinha, Shirshendu; Gastineau, Dennis A.; Wolf, Robert; Inw 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 292 KB

A Cost Effective Analysis of a Risk-Adap

✍ I.N. Micallef; S. Sinha; D.A. Gastineau; R. Wolf; D.J. Inwards; M.A. Gertz; S.R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Cost and Clinical Analysis of Autologous

✍ Paul Shaughnessy; Miguel Islas-Ohlmayer; Julie Murphy; Maureen Hougham; Jill Mac 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 340 KB

Development and validation of a decision

✍ Costa, L J; Alexander, E T; Hogan, K R; Schaub, C; Fouts, T V; Stuart, R K 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 322 KB